Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F11%3A33117035" target="_blank" >RIV/61989592:15310/11:33117035 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.2174/156800911794519806" target="_blank" >http://dx.doi.org/10.2174/156800911794519806</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/156800911794519806" target="_blank" >10.2174/156800911794519806</a>

Result language
angličtina
Original language name
Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Original language description
An old drug, Antabuse (disulfiram), used for decades in alcohol aversion therapy, and its metabolite Ditiocarb were shown from 1970s to suppress cancer growth in vivo and even in human patients. The drug targets multidrug resistance, angiogenesis, invasion, and proteasome. Today, there are ongoing clinical trials of Antabuse as an adjuvant therapy against lung cancer and as a monotherapy against cancers metastasizing to liver. The larger clinical trials, if appropriate, will need support from governments and charities to get the generic drug into the clinic as a "non-profit" drug.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/GP303%2F08%2FP137" target="_blank" >GP303/08/P137: Influence of dithiocarbamate complexes with Pt(II) and Au(III) on NF-?B pathway in human tumor lines HepG2 and SK-HEP-1</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)